In addition, the serum levels of galectin-9 have been found significantly increased in CLL patients compared with the control group and have been associated with poor cytogenetic and serum prognostic factors and treatment failure [183]. This evidence concerns the gene LGALS9 and B-cell chronic lymphocytic leukemia.